Related Parties

12 Months Ended

Dec. 31, 2014

Related Party Transactions [Abstract]

Related Party Disclosure

28.       Related parties

Shire considers that ArmaGen is a related party by virtue of a combination of Shire's 18% equity stake in ArmaGen and the worldwide licensing and collaboration agreement between the two parties to develop and commercialize AGT-182 (see Note 18 for details). In the year to December 31, 2014, Shire paid $15 million in cash to ArmaGen in exchange for an equity stake in ArmaGen and the license to develop and commercialize AGT-182. In addition, Shire's share of R&D costs under the collaboration arrangement during 2014 was $1.7million, recorded within R&D expense in the consolidated income statement, of which $1.0 million was accrued as at December 31, 2014.

Shire considers that ArmaGen is a related party by virtue of a combination of Shire's 18% equity stake in ArmaGen and the worldwide licensing and collaboration agreement between the two parties to develop and commercialize AGT-182 (see Note 18 for details). In the year to December 31, 2014, Shire paid $15 million in cash to ArmaGen in exchange for an equity stake in ArmaGen and the license to develop and commercialize AGT-182. In addition, Shire's share of R&D costs under the collaboration arrangement during 2014 was $1.7million, recorded within R&D expense in the consolidated income statement, of which $1.0 million was accrued as at December 31, 2014.